Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Picks Venture Capitalist Ashrafian To Succeed Reed As R&D Head

Co-Founded Seven Biotechs

Executive Summary

The French drugmaker is banking on the wealth of expertise that Houman Ashrafian brings as both a scientist and biotech entrepreneur to drive forward its R&D efforts.

You may also be interested in...



J.P. Morgan Day Three: Biogen Still Shopping For Deals, Sanofi Explains Its View On Oncology

Daily notebook from the J.P. Morgan Healthcare Conference: Biogen is still looking for deals, just smaller; Sanofi's push in immunology has pulled it away from oncology; Sage provides updates on Zurzuvae launch; and Takeda plans a big program for its TYK-2 inhibitor. 

Sanofi Eyes External Deals On Top Of Promising Pipeline

The French drugmaker is significantly upping its investments in R&D but recent major deals with J&J and Teva show that Sanofi is still open to expanding its external programs as well.

Sanofi Moves Up In MS With Frexalimab Success

Much of the focus on the French major’s MS pipeline has been on the BTK inhibitor tolebrutinib but promising Phase II data on frexalimab have caught the eye.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel